Pages that link to "Q28221401"
Jump to navigation
Jump to search
The following pages link to Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease (Q28221401):
Displaying 30 items.
- Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis (Q22241651) (← links)
- Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies (Q24235107) (← links)
- Use of ibuprofen and risk of Parkinson disease (Q24863751) (← links)
- Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies (Q26795984) (← links)
- Neuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugs (Q26801035) (← links)
- M1 and M2 immune activation in Parkinson's Disease: Foe and ally? (Q27024667) (← links)
- The epidemiology of Parkinson's disease: risk factors and prevention (Q30244421) (← links)
- Brain arachidonic acid cascade enzymes are upregulated in a rat model of unilateral Parkinson disease (Q33718730) (← links)
- Catalytic antioxidants and neurodegeneration (Q34104938) (← links)
- Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study (Q34505182) (← links)
- Non-steroidal anti-inflammatory drug use and the risk of Parkinson's disease (Q34985170) (← links)
- The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research (Q36048230) (← links)
- Eicosanoid receptor subtype-mediated opposing regulation of TLR-stimulated expression of astrocyte glial-derived neurotrophic factor (Q36055556) (← links)
- Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation (Q36453886) (← links)
- NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies (Q37591516) (← links)
- Inflammatory response in Parkinsonism. (Q37735815) (← links)
- Parkinson's disease: evidence for environmental risk factors (Q38055457) (← links)
- Neural and immune mechanisms in the pathogenesis of Parkinson's disease. (Q38078895) (← links)
- Osteoarthritis of the hand II: chemistry, pharmacokinetics and pharmacodynamics of naproxen, and clinical outcome studies (Q38157117) (← links)
- Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation. (Q38974344) (← links)
- Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson's Disease (Q39392775) (← links)
- Inflammatory Mechanisms of Neurodegeneration in Toxin-Based Models of Parkinson's Disease (Q41917715) (← links)
- Polymer brain-nanotherapeutics for multipronged inhibition of microglial α-synuclein aggregation, activation, and neurotoxicity. (Q45814729) (← links)
- Updates on immunity and inflammation in Parkinson disease pathology (Q46132067) (← links)
- Sodium salicylate protects against rotenone-induced parkinsonism in rats (Q48145970) (← links)
- Preceding pain symptoms and Parkinson's disease: a nationwide population-based cohort study (Q48474282) (← links)
- Non-steroidal anti-inflammatory drugs and risk of Parkinson's disease in the elderly population: a meta-analysis (Q57045903) (← links)
- NSAID use and risk of Parkinson disease: a population-based case-control study (Q57950713) (← links)
- Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: A dose-response meta-analysis (Q58739806) (← links)
- Lipid transporter Spns2 promotes microglia pro-inflammatory activation in response to amyloid-beta peptide (Q93365978) (← links)